Navigation Links
Hard To Treat Diseases (HTDS) Announces Initial Research Results on Potential MS Therapy
Date:2/2/2009

Research results with animal testing encouraging

BELGRADE, Serbia, Feb. 2 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com announced the results of preliminary testing of a potential treatment for Multiple Sclerosis.

Testing involved the use of a combination of drugs; ribavirin and tiazofurin on animal test subjects. Administration of ribavirin and tiazofurin in combination attenuated or weakened the proliferation of autoreactive T lymphocytes and their infiltration into the nervous tissue that are involved in the destruction of myelin, oligodendrocytes and axons associated with MS. The tests succeeded in decreasing clinical symptoms and duration of the disease induced in experimental animals. These results are encouraging for the future MS therapy.

Also encouraging is the fact that the two drugs in question are currently used in treatment or undergoing clinical trials in relation to the treatment of other diseases. In particular, ribavirin is already in use in human clinical practice as an antiviral drug (VIRAZOL), and is very successful in treatment of respiratory syncicial virus in children, hepatitis C, SARS and HIV. Tiazofurin is in phase II of clinical trials as an anticancer drug.

Multiple sclerosis is a chronic disease with severe neurological symptoms, which often leads to complete disability and death. To date there is no suitable therapy for this heavy neurological disorder.

The company will provide further details as they become available.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

Get the Facts Right. The issuer works hard to continue to keep our shareholders informed, and news is updated frequently via Press Releases, Pink Sheet filings (www.pinksheets.com), and updates to our websites. Other websites not sponsored, or recognized by the Company may provide misleading or disinformation to investors in order to manipulate trading patterns for a given stock. Always look for original content from trusted sources, rather than relying on 'excerpts' or discussion boards that may not give you the whole story. The Securities and Exchange Commission requires financial institutions or brokerage firms to provide their clients with documentation describing the risks of investing in penny stocks.

CONTACT: For scientific dialogue and inquiry only Andrea can be reached via e-mail at azconsulting2001@gmail.com; For any corporate matters the readers should contact the company directly at corporate@htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Less Than Two-Thirds of Surveyed Pharmacy Directors Expect to Reimburse Both Onglyza and Alogliptin Once They are Available for the Treatment of Type 2 Diabetes
2. Top Belgian Cancer Center Becomes First in Country to Introduce RapidArc Radiotherapy Treatments From Varian Medical Systems
3. Aggressive Treatment Effective in Kids Brain Cancer
4. The American Academy of Periodontology issues statement on periodontal treatment during pregnancy
5. Drug combinations key in treating neurodegenerative diseases
6. GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer
7. Under-Treatment of Pain Exacerbated by Public Perceptions of Medicines and Safety
8. Gum Disease Treatment Doesnt Cut Preterm Birth Risk
9. Process found to play role in rheumatoid arthritis could lead to new treatment
10. Alliance of Experts Created to Help Raise Awareness of Best Practices in Diabetes Treatment
11. Novartis Oncology Launches GIST Alliance™ for Healthcare Professionals Treating Gastrointestinal Stromal Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 21, 2017 , ... ... Dermatology has recently joined their multi-specialty medical group. The dermatology practice provides ... services. , “We’re excited to add this excellent dermatology practice to our group’s ...
(Date:1/20/2017)... ... January 20, 2017 , ... A new partnership between Goodwill® ... no longer use or need, from clothes to couches to dressers and bicycles. Roadie ... take them to the nearest Goodwill donation center through February 28th. , “January ...
(Date:1/20/2017)... ... 20, 2017 , ... Lice Troopers, the lice removal company based in South ... since the holiday season. , “It happens every year around this time,” says ... taking photos, which is the head-to-head gateway that lice need to spread.” , As ...
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin Well ... VW+ 002. The drinks have been produced in collaboration with Zlatan Ibrahimovic and ... your workout. , After a successful launch in Sweden last year, the next ...
(Date:1/20/2017)... ... January 20, 2017 , ... D R ... Pressure (OPEP) device, was featured in a study indicating superior performance against competitive ... “Analysis of Three Oscillating Positive Expiratory Pressure Devices During Simulated Breathing“ was ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... 2017 According to a new market research ... R&D, Compliance, SCM), Component (Software, Service), Delivery (On premise, Cloud), End ... by MarketsandMarkets, the market is expected to reach USD 24.73 Billion ... of 13.3% during the forecast period. ... ...
(Date:1/20/2017)... 2017 Research and Markets has announced ... ([CBC, HGB/HCT, BMP, BUN Creatinine, Electrolyte Testing, HbA1c Testing, Comprehensive Metabolic ... Forecasts, 2013 - 2024" report to their offering. ... The global clinical laboratory ... Introduction of innovative solutions on the grounds of maximum ...
(Date:1/20/2017)... 20, 2017  Palladian Health, a leading provider ... launch of an opioid management program which assists ... and helps stem the growing tide of dependence ... treat chronic non-cancer pain (back pain, neck pain, ... lack of evidence regarding long-term effectiveness. ...
Breaking Medicine Technology: